Early treatment of lupus helps improve outcomes for patients. Finding better blood tests to predict what is about to happen with lupus disease activity could alert doctors to changes in a patient’s condition that otherwise might not be obvious.
Investigators at UCLA believe they have discovered an antibody in the blood, MAGE-B2, which may be associated with lupus kidney disease in children and could possibly serve as a biomarker. If future studies continue to show an association between the MAGE-B2 antibody and lupus, or even more particularly lupus nephritis, doctors should be able to treat lupus earlier to prevent damage.
Read more about this study.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment